Search Results for "Hypertension"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Hypertension. Results 361 to 370 of 401 total matches.

Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022  (Issue 1643)
, and intracranial hypertension with papilledema, visual changes, headache, and nausea and/or vomiting may occur ...
Lonapegsomatropin-tcgd (Skytrofa – Ascendis), a long-acting prodrug of recombinant human growth hormone (rhGH), has been approved by the FDA for once-weekly subcutaneous (SC) treatment of growth failure due to inadequate secretion of endogenous growth hormone in children ≥1 year old who weigh ≥11.5 kg. It is the first once-weekly rhGH product to be approved in the US; other available rhGH formulations are administered more frequently.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):20-2 |  Show IntroductionHide Introduction

Drugs of Choice for Cancer Chemotherapy

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 1995  (Issue 945)
retention with edema; hypertension; change in menstrual flow Docetaxel (Taxotere − Aventis ...
Med Lett Drugs Ther. 1995 Mar 31;37(945):25-32 |  Show IntroductionHide Introduction

Drugs for ADHD

   
The Medical Letter on Drugs and Therapeutics • Jan 27, 2020  (Issue 1590)
can result in hypertensive crisis and is contraindicated; stimulants should not be taken ...
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood. A study in a large Danish cohort found that ADHD was associated with higher mortality rates in children, adolescents, and adults, mainly due to accidents. Pharmacologic treatment of ADHD in children has been reported to decrease the risk of substance abuse in adolescents, and use of ADHD medications in adults has been associated with a reduced risk of serious traffic accidents and...
Med Lett Drugs Ther. 2020 Jan 27;62(1590):9-15 |  Show IntroductionHide Introduction

Drugs for Anxiety Disorders

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023  (Issue 1682)
, tachycardia, hypertension, agitation, tremor, myoclonus, hyperreflexia, ataxia, incoordination, diaphoresis ...
Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8   doi:10.58347/tml.2023.1682a |  Show IntroductionHide Introduction

Dehydroepiandrosterone (DHEA)

   
The Medical Letter on Drugs and Therapeutics • May 09, 2005  (Issue 1208)
. Hirsutism and voice changes may be irreversible. Hepatic dysfunction and hypertension have occurred. Acute ...
Dehydroepiandrosterone (DHEA), an endogenous adrenal steroid, is marketed as a dietary supplement in the US. It is widely promoted to reverse the effects of aging (loss of muscle, memory and libido) and has been used by athletes as a substitute for anabolic steroids. DHEA is banned by the International Olympic Committee, National Collegiate Athletic Association, National Football League and other sports organizations, but it was specifically exempted from becoming a controlled substance in the Anabolic Steroid Control Act of 2004.
Med Lett Drugs Ther. 2005 May 9;47(1208):37-8 |  Show IntroductionHide Introduction

H1N1 Vaccine for Prevention of Pandemic Influenza

   
The Medical Letter on Drugs and Therapeutics • Oct 05, 2009  (Issue 1322)
asthma), cardiovascular (except hypertension), renal, hepatic, cognitive, neurologic, hematologic ...
The FDA has licensed 4 new monovalent vaccines for prevention of respiratory illness caused by a new influenza A H1N1 virus that appears to be derived from a swine strain. The 5th vaccine should be licensed soon. All of these vaccines are expected to become available in October. An intranasal formulation is expected in the first week of October.
Med Lett Drugs Ther. 2009 Oct 5;51(1322):77-8 |  Show IntroductionHide Introduction

Jornay PM - Evening-Dosed Methylphenidate for ADHD

   
The Medical Letter on Drugs and Therapeutics • Aug 12, 2019  (Issue 1578)
such as methylphenidate and a monoamine oxidase (MAO) inhibitor can result in hypertensive crisis and is contraindicated ...
The FDA has approved Jornay PM (Ironshore), a capsule formulation of methylphenidate with a delayed-release outer layer and an extended-release inner layer, for once-nightly treatment of attention-deficit hyperactivity disorder (ADHD) in patients >6 years old. Jornay PM is the first methylphenidate product to become available in the US that is taken in the evening; other long-acting methylphenidate formulations are taken in the morning. It is being marketed specifically for patients who have disruptive ADHD symptoms in the morning.
Med Lett Drugs Ther. 2019 Aug 12;61(1578):126-8 |  Show IntroductionHide Introduction

Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
reactions, hypertension, neutropenia, elevated serum transaminase levels, and dyslipidemia can occur ...
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Med Lett Drugs Ther. 2021 Nov 15;63(1637):e187-9 |  Show IntroductionHide Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2023  (Issue 1676)
and extended-cycle or continuous regimens, particularly during initial cycles. Women with hypertension taking ...
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also effective in preventing pregnancy. When used alone, barrier and behavioral methods generally have higher failure rates than other methods (see Table 1). Selection of a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80   doi:10.58347/tml.2023.1676a |  Show IntroductionHide Introduction

Pramipexole (Mirapex) for Restless Leg Syndrome

   
The Medical Letter on Drugs and Therapeutics • Mar 26, 2007  (Issue 1257)
Letter: Aliskiren (Tekturna) for Hypertension Female Sexual Dysfunction Dermal Fillers Coming Soon ...
The dopamine agonist pramipexole (Mirapex - Boehringer Ingelheim) is the second drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS). Ropinirole (Requip), another dopamine agonist, was approved for RLS in 2005. Both of these drugs were first approved for treatment of Parkinson's disease.
Med Lett Drugs Ther. 2007 Mar 26;49(1257):26-8 |  Show IntroductionHide Introduction